ANTX (STOCKS)
AN2 Therapeutics, Inc. Common Stock
$2.980000
+0.010000 (+0.34%)
Prev close: $2.970000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Eric Easom
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $108.18M
- Employees
- 36
- P/E (TTM)
- -2.59
- P/B (TTM)
- 1.53
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $37.39M |
| Research and Development | $23.29M |
| Other Operating Expenses | $14.10M |
| Operating Income/Loss | -$37.39M |
| Income/Loss From Continuing Operations After Tax | -$33.99M |
| Income/Loss From Continuing Operations Before Tax | -$33.99M |
| Net Income/Loss | -$33.99M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$12.00K |
| Net Income/Loss Attributable To Parent | -$33.97M |
| Net Income/Loss Available To Common Stockholders, Basic | -$33.99M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $12.00K |
| Preferred Stock Dividends And Other Adjustments | $12.00K |
| Basic Earnings Per Share | -$1.13 |
| Diluted Earnings Per Share | -$1.13 |
| Basic Average Shares | 60,407,939 |
| Diluted Average Shares | 60,407,939 |
| Assets | $67.24M |
| Current Assets | $64.02M |
| Noncurrent Assets | $3.22M |
| Liabilities | $6.86M |
| Current Liabilities | $6.86M |
| Accounts Payable | $2.23M |
| Wages | $1.74M |
| Other Current Liabilities | $2.89M |
| Noncurrent Liabilities | $0.00 |
| Equity | $60.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $60.38M |
| Liabilities And Equity | $67.24M |
| Net Cash Flow From Operating Activities | -$29.87M |
| Net Cash Flow From Operating Activities, Continuing | -$29.87M |
| Net Cash Flow From Investing Activities | $14.26M |
| Net Cash Flow From Investing Activities, Continuing | $14.26M |
| Net Cash Flow From Financing Activities | $113.00K |
| Net Cash Flow From Financing Activities, Continuing | $113.00K |
| Net Cash Flow | -$15.50M |
| Net Cash Flow, Continuing | -$15.50M |
| Comprehensive Income/Loss | -$34.03M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$34.03M |
| Other Comprehensive Income/Loss | -$9.40M |